查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1941884

病毒载体市场规模、份额和趋势分析报告：按载体类型、应用、最终用途、地区和细分市场预测（2026-2033 年）

Viral Vector Market Size, Share & Trends Analysis Report By Vector Type (AAV, Adenovirus, Lentivirus, Retrovirus), By Application (Cell & Gene Therapy, Vaccine), By End Use, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 180 Pages | 商品交期: 2-10个工作天内

价格

病毒载体市场概述

2025年全球病毒载体市场规模估计为42.5亿美元，预计2033年将达到102.2亿美元。

预计从 2026 年到 2033 年，该市场将以 11.69% 的复合年增长率成长。目标疾病和遗传性疾病的日益普遍，以及数位诊断技术的进步，预计将支持病毒载体市场的成长。

此外，病毒载体在基因治疗中疗效的提升也促进了市场成长。遗传疾病和感染疾病的不断增加预计将推动对病毒载体的需求成长。例如，根据联合国爱滋病规划署（UNAIDS）的数据，到2024年，全球将有约4,080万人感染爱滋病毒。这种情况正在推动市场成长。此外，政府主导的各项倡议，例如直接增加对创新临床疗法的需求、为病毒载体生产提供资金，以及对新兴的遗传疾病治疗领域日益增长的关注（该领域正透过技术主导取得进展），都在推动市场扩张。

在基因和细胞疗法研发、疫苗创新以及先进生物製药製造的强劲发展势头推动下，市场持续快速扩张。在这个市场环境下，随着越来越多的治疗方法从临床试验走向商业化，病毒载体製造和生产市场需求持续旺盛，对扩充性的、符合GMP规范的生产能力提出了更高的要求。同时，病毒载体和质体DNA製造市场的策略重要性日益凸显，因为质体DNA是病毒载体生产的关键原料，直接影响产量、品质和生产进度。此外，儘管病毒载体在临床研发管线中仍占据主导地位，但由于人们对具有安全性、可重复性和易于生产等优势的替代递送技术的兴趣日益浓厚，非病毒载体行业正逐渐成为一个补充领域。

从经营模式角度来看，病毒载体CDMO市场是产业成长的核心支柱，因为生物製药公司越来越多地将研发和生产外包给专业合作伙伴，以降低资本风险并缩短产品上市时间。 CDMO公司正在扩展其能力，以处理多种载体类型，并提供整合质体DNA供应、上游工程和下游加工以及分析服务的端到端解决方案。此外，病毒载体疫苗市场持续推动整体需求，这得益于近期全球健康倡议中平台有效性的检验以及感染疾病和肿瘤疫苗的持续研发。这些相互关联的细分市场共同构成了一个充满活力且资本密集的市场，而扩大产能、技术创新和策略合作对于长期成长仍然至关重要。

目录

第一章：调查方法和范围

第二章执行摘要

第三章 市场变数、趋势与范围

  • 市场区隔和范围
  • 市场体系展望
    • 母市场展望
    • 相关及补贴市场展望
  • 市场趋势与展望
  • 市场动态
  • 市场限制因素分析
    • 复杂的製造流程。
    • 监管挑战和智慧财产权问题。
  • 商业环境分析
    • SWOT分析；以因素（政治/监管、经济、技术）进行分析
    • 波特五力分析

第四章：病毒载体市场：依载体类型分類的市场规模估算与趋势分析

  • 病毒载体市场：按载体类型分類的波动分析
  • 腺结合病毒（AAV）
  • 腺病毒
  • 慢病毒
  • 逆转录病毒
  • 其他的

第五章：病毒载体市场：按应用分類的规模估算与趋势分析

  • 病毒载体市场：基于应用的波动分析
  • 细胞和基因治疗
  • 疫苗
  • 生物製药和药物研发

第六章：病毒载体市场：依最终用途分類的市场规模估算与趋势分析

  • 病毒载体市场：终端用途波动分析
  • 製药和生物技术公司
  • 学术和研究机构
  • 合约研究组织 (CRO) 和合约行销组织 (CMO)

第七章：病毒载体市场：区域规模估算与趋势分析

  • 病毒载体的区域市场占有率（2025 年和 2033 年）
  • 北美洲
  • 欧洲
  • 亚太地区
  • 拉丁美洲
  • 中东和非洲

第八章 竞争情势

  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Oxford Biomedica
    • Thermo Fisher Scientific, Inc.
    • Lonza.
    • Batavia Biosciences BV
    • Biogen
    • Asklepios BioPharmaceutical, Inc.（AskBio）
    • Sanofi
    • Spark Therapeutics, Inc.
    • Regenxbio Inc.
    • uniQURE NV
Product Code: GVR-4-68040-072-3

Viral Vector Market Summary

The global viral vector market size was estimated at USD 4.25 billion in 2025 and is projected to reach USD 10.22 billion by 2033, growing at a CAGR of 11.69% from 2026 to 2033. The increasing prevalence of target diseases and genetic disorders, along with technological advancements in digital diagnostics, is expected to support the market growth for viral vectors.

Furthermore, increasing the effectiveness of viral vectors in gene therapy delivery is contributing to the market growth. The rising prevalence of genetic disorders and contagious diseases is anticipated to boost the demand for viral vectors. For instance, according to the Joint United Nations Programme on HIV/AIDS (UNAIDS) data, around 40.8 million people were living with HIV in 2024. This is fueling market growth. Furthermore, government initiatives such as direct growing demand for innovative clinical therapies, funding for viral vector manufacturing, and an increasing focus on the emerging area of medicine for genetic disorders, which has been helped by transforming techniques, are driving market expansion.

The market continues to expand rapidly, underpinned by strong momentum in gene and cell therapy development, vaccine innovation, and advanced biologics manufacturing. Within this landscape, the viral vector manufacturing market and viral vector production market are seeing sustained demand as more therapies transition from clinical trials to commercialization, creating pressure on scalable, GMP-compliant capacity. At the same time, the viral vector and plasmid DNA manufacturing market is gaining strategic importance, as plasmid DNA remains a critical raw material for viral vector production, directly influencing yield, quality, and timelines. In parallel, while viral vectors dominate clinical pipelines, the non-viral vector industry is emerging as a complementary space, driven by interest in alternative delivery technologies that offer advantages in safety, repeat dosing, and manufacturing simplicity for certain applications.

From a business model perspective, the viral vector CDMO market has become a central pillar of industry growth, as biopharma companies increasingly outsource development and manufacturing to specialized partners to reduce capital risk and accelerate time to market. CDMOs are expanding capabilities across multiple vector types, integrating plasmid DNA supply, upstream and downstream processing, and analytical services to offer end-to-end solutions. In addition, the viral vector vaccines market continues to contribute to overall demand, supported by platform validation during recent global health initiatives and ongoing development of vaccines for infectious diseases and oncology indications. Together, these interconnected segments are shaping a dynamic and capital-intensive market, where capacity expansion, technological innovation, and strategic partnerships remain critical to long-term growth.

Global Viral Vector Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global viral vector market based on vector type, application, end use, and region:

  • Vector Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Adeno-associated virus (AAV)
  • Adenovirus
  • Lentivirus
  • Retrovirus
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cell & Gene Therapy
  • Vaccine
  • Biopharmaceutical & Pharmaceutical Discovery
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharmaceutical and Biotechnology Companies
  • Academics and Research Institutes
  • CROs & CMOs
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Vector Type
    • 1.2.2. Application
    • 1.2.3. End use
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives
    • 1.10.1. Objective 1
    • 1.10.2. Objective 2

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
    • 3.4.1. Increasing demand for gene therapies
    • 3.4.2. Rising investments in research and development with immense funding support
  • 3.5. Market Restraint Analysis
    • 3.5.1. Complex manufacturing process.
    • 3.5.2. Regulatory challenges and intellectual property issues.
  • 3.6. Business Environment Analysis
    • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
    • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Viral Vector Market: Vector Type Size Estimated & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Viral vector market: Vector Type Movement Analysis
  • 4.3. Adeno-associated virus (AAV)
    • 4.3.1. Adeno-associated virus (AAV) Market, 2021 - 2033 (USD Million)
  • 4.4. Adenovirus
    • 4.4.1. Adenovirus Market, 2021 - 2033 (USD Million)
  • 4.5. Lentivirus
    • 4.5.1. Lentivirus Market, 2021 - 2033 (USD Million)
  • 4.6. Retrovirus
    • 4.6.1. Retrovirus Market, 2021 - 2033 (USD Million)
  • 4.7. Others
    • 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Viral Vector Market: Application Size Estimated & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Viral vector market: Application Movement Analysis
  • 5.3. Cell and Gene Therapy
    • 5.3.1. Cell and Gene Therapy Market, 2021 - 2033 (USD Million)
  • 5.4. Vaccine
    • 5.4.1. Vaccine Market, 2021 - 2033 (USD Million)
  • 5.5. Biopharmaceutical & Pharmaceuticals Discovery
    • 5.5.1. Biopharmaceutical & Pharmaceuticals Discovery Market, 2021 - 2033 (USD Million)

Chapter 6. Viral Vector Market: End Use Size Estimated & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Viral vector market: End Use Movement Analysis
  • 6.3. Pharmaceutical and Biotechnology Companies
    • 6.3.1. Pharmaceutical and Biotechnology Companies Market, 2021 - 2033 (USD Million)
  • 6.4. Academic and Research Institutes
    • 6.4.1. Academic and Research Institutes Market, 2021 - 2033 (USD Million)
  • 6.5. CROs & CMOs
    • 6.5.1. CROs and CMOs Market, 2021 - 2033 (USD Million)

Chapter 7. Viral Vector Market: Regional Size Estimated & Trend Analysis

  • 7.1. Viral Vector Market Share by Region, 2025 & 2033
  • 7.2. North America
    • 7.2.1. North America Viral vector market, 2021 - 2033 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. Key Country Dynamics
      • 7.2.2.2. Competitive Scenario
      • 7.2.2.3. Regulatory Framework
      • 7.2.2.4. U.S. viral vector market, 2021 - 2033 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Key Country Dynamics
      • 7.2.3.2. Competitive Scenario
      • 7.2.3.3. Regulatory Framework
      • 7.2.3.4. Canada Viral vector market, 2021 - 2033 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Key Country Dynamics
      • 7.2.4.2. Competitive Scenario
      • 7.2.4.3. Regulatory Framework
      • 7.2.4.4. Mexico Viral vector market, 2021 - 2033 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.2. Germany
      • 7.3.2.1. Key Country Dynamics
      • 7.3.2.2. Competitive Scenario
      • 7.3.2.3. Regulatory Framework
      • 7.3.2.4. Germany Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.3. UK
      • 7.3.3.1. Key Country Dynamics
      • 7.3.3.2. Competitive Scenario
      • 7.3.3.3. Regulatory Framework
      • 7.3.3.4. UK Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. Key Country Dynamics
      • 7.3.4.2. Competitive Scenario
      • 7.3.4.3. Regulatory Framework
      • 7.3.4.4. France Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Key Country Dynamics
      • 7.3.5.2. Competitive Scenario
      • 7.3.5.3. Regulatory Framework
      • 7.3.5.4. Italy Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Key Country Dynamics
      • 7.3.6.2. Competitive Scenario
      • 7.3.6.3. Regulatory Framework
      • 7.3.6.4. Spain Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Key Country Dynamics
      • 7.3.7.2. Competitive Scenario
      • 7.3.7.3. Regulatory Framework
      • 7.3.7.4. Denmark Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Key Country Dynamics
      • 7.3.8.2. Competitive Scenario
      • 7.3.8.3. Regulatory Framework
      • 7.3.8.4. Sweden Viral vector market, 2021 - 2033 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Key Country Dynamics
      • 7.3.9.2. Competitive Scenario
      • 7.3.9.3. Regulatory Framework
      • 7.3.9.4. Norway Viral vector market, 2021 - 2033 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Viral vector market, 2021 - 2033 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Competitive Scenario
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Japan Viral vector market, 2021 - 2033 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Competitive Scenario
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. China Viral vector market, 2021 - 2033 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Competitive Scenario
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. India Viral vector market, 2021 - 2033 (USD Million)
    • 7.4.5. South Korea
      • 7.4.5.1. Key Country Dynamics
      • 7.4.5.2. Competitive Scenario
      • 7.4.5.3. Regulatory Framework
      • 7.4.5.4. South Korea Viral vector market, 2021 - 2033 (USD Million)
    • 7.4.6. Australia
      • 7.4.6.1. Key Country Dynamics
      • 7.4.6.2. Competitive Scenario
      • 7.4.6.3. Regulatory Framework
      • 7.4.6.4. Australia Viral vector market, 2021 - 2033 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Key Country Dynamics
      • 7.4.7.2. Competitive Scenario
      • 7.4.7.3. Regulatory Framework
      • 7.4.7.4. Thailand Viral vector market, 2021 - 2033 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Viral vector market, 2021 - 2033 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Competitive Scenario
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Brazil Viral vector market, 2021 - 2033 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Competitive Scenario
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Argentina Viral vector market, 2021 - 2033 (USD Million)
  • 7.6. MEA
    • 7.6.1. MEA Viral vector market, 2021 - 2033 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Competitive Scenario
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. South Africa Viral vector market, 2021 - 2033 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Competitive Scenario
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Saudi Arabia Viral vector market, 2021 - 2033 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Competitive Scenario
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. UAE Viral vector market, 2021 - 2033 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Competitive Scenario
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Kuwait Viral vector market, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Profiles/Listing
    • 8.3.1. Oxford Biomedica
      • 8.3.1.1. Overview
      • 8.3.1.2. Financial Performance
      • 8.3.1.3. Product Benchmarking
      • 8.3.1.4. Strategic Initiatives
    • 8.3.2. Thermo Fisher Scientific, Inc.
      • 8.3.2.1. Overview
      • 8.3.2.2. Financial Performance
      • 8.3.2.3. Product Benchmarking
      • 8.3.2.4. Strategic Initiatives
    • 8.3.3. Lonza.
      • 8.3.3.1. Overview
      • 8.3.3.2. Financial Performance
      • 8.3.3.3. Product Benchmarking
      • 8.3.3.4. Strategic Initiatives
    • 8.3.4. Batavia Biosciences B.V.
      • 8.3.4.1. Overview
      • 8.3.4.2. Financial Performance
      • 8.3.4.3. Product Benchmarking
      • 8.3.4.4. Strategic Initiatives
    • 8.3.5. Biogen
      • 8.3.5.1. Overview
      • 8.3.5.2. Financial Performance
      • 8.3.5.3. Product Benchmarking
      • 8.3.5.4. Strategic Initiatives
    • 8.3.6. Asklepios BioPharmaceutical, Inc. (AskBio)
      • 8.3.6.1. Overview
      • 8.3.6.2. Financial Performance
      • 8.3.6.3. Product Benchmarking
      • 8.3.6.4. Strategic Initiatives
    • 8.3.7. Sanofi
      • 8.3.7.1. Overview
      • 8.3.7.2. Financial Performance
      • 8.3.7.3. Product Benchmarking
      • 8.3.7.4. Strategic Initiatives
    • 8.3.8. Spark Therapeutics, Inc.
      • 8.3.8.1. Overview
      • 8.3.8.2. Financial Performance
      • 8.3.8.3. Product Benchmarking
      • 8.3.8.4. Strategic Initiatives
    • 8.3.9. Regenxbio Inc.
      • 8.3.9.1. Overview
      • 8.3.9.2. Financial Performance
      • 8.3.9.3. Product Benchmarking
      • 8.3.9.4. Strategic Initiatives
    • 8.3.10. uniQURE N.V.
      • 8.3.10.1. Overview
      • 8.3.10.2. Financial Performance
      • 8.3.10.3. Product Benchmarking
      • 8.3.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 Global viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 3 Global viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 4 Global viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 5 Global viral vector market, by region, 2021 - 2033 (USD Million)
  • Table 6 North America viral vector market, by country, 2021 - 2033 (USD Million)
  • Table 7 North America viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 8 North America viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 9 North America viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 10 U.S. viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 11 U.S. viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 12 U.S. viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 13 Canada viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 14 Canada viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 15 Canada viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 16 Mexico viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 17 Mexico viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 18 Mexico viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 19 Europe viral vector market, by country, 2021 - 2033 (USD Million)
  • Table 20 Europe viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 21 Europe viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 22 Europe viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 23 Germany viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 24 Germany viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 25 Germany viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 26 UK viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 27 UK viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 28 UK viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 29 France viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 30 France viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 31 France viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 32 Italy viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 33 Italy viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 34 Italy viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 35 Spain viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 36 Spain viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 37 Spain viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 38 Denmark viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 39 Denmark viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 40 Denmark viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 41 Sweden viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 42 Sweden viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 43 Sweden viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 44 Norway viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 45 Norway viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 46 Norway viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 47 Asia Pacific viral vector market, by country, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 51 China viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 52 China viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 53 China viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 54 Japan viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 55 Japan viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 56 Japan viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 57 India viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 58 India viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 59 India viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 60 South Korea viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 61 South Korea viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 62 South Korea viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 63 Australia viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 64 Australia viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 65 Australia viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 66 Thailand viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 67 Thailand viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 68 Thailand viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 69 Latin America viral vector market, by country, 2021 - 2033 (USD Million)
  • Table 70 Latin America viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 71 Latin America viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 72 Latin America viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 73 Brazil viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 74 Brazil viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 75 Brazil viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 76 Argentina viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 77 Argentina viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 78 Argentina viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 79 Middle East & Africa viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 82 South Africa viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 83 South Africa viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 84 South Africa viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 85 Saudi Arabia viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 86 Saudi Arabia viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 88 UAE viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 89 UAE viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 90 UAE viral vector market, by end use, 2021 - 2033 (USD Million)
  • Table 91 Kuwait viral vector market, by vector type, 2021 - 2033 (USD Million)
  • Table 92 Kuwait viral vector market, by application, 2021 - 2033 (USD Million)
  • Table 93 Kuwait viral vector market, by end use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 Market formulation & validation
  • Fig. 7 Viral vector market segmentation
  • Fig. 8 Market snapshot, 2025
  • Fig. 9 Market trends & outlook
  • Fig. 10 Market driver relevance analysis (current & future impact)
  • Fig. 11 Market restraint relevance analysis (current & future impact)
  • Fig. 12 Swot analysis, by factor (political & legal, economic and technological)
  • Fig. 13 Porter's five forces analysis
  • Fig. 14 Global viral vector market: vector type movement analysis
  • Fig. 15 Global viral vector market, for adeno-associated virus (AAV), 2021 - 2033 (USD Million)
  • Fig. 16 Global viral vector market, for adenovirus, 2021 - 2033 (USD Million)
  • Fig. 17 Global viral vector market, for lentivirus, 2021 - 2033 (USD Million)
  • Fig. 18 Global viral vector market, for retrovirus, 2021 - 2033 (USD Million)
  • Fig. 19 Global viral vector market, for others, 2021 - 2033 (USD Million)
  • Fig. 20 Global viral vector market: application movement analysis
  • Fig. 21 Global viral vector market, for cell & gene therapy, 2021 - 2033 (USD Million)
  • Fig. 22 Global viral vector market, for vaccine, 2021 - 2033 (USD Million)
  • Fig. 23 Global viral vector market, for biopharmaceutical and pharmaceutical discovery, 2021 - 2033 (USD Million)
  • Fig. 24 Global viral vector market: End use movement analysis
  • Fig. 25 Global viral vector market, for pharmaceutical and biotechnology companies, 2021 - 2033 (USD Million)
  • Fig. 26 Global viral vector market, for academic and research institutes, 2021 - 2033 (USD Million)
  • Fig. 27 Global viral vector market, for CROs and CMOs, 2021 - 2033 (USD Million)
  • Fig. 28 Regional marketplace: key takeaways
  • Fig. 29 Regional outlook, 2025 & 2033
  • Fig. 30 Global viral vector market: region movement analysis
  • Fig. 31 North America viral vector market, 2021 - 2033 (USD Million)
  • Fig. 32 U.S. Viral vector market, 2021 - 2033 (USD Million)
  • Fig. 33 Canada viral vector market, 2021 - 2033 (USD Million)
  • Fig. 34 Mexico viral vector market, 2021 - 2033 (USD Million)
  • Fig. 35 Europe viral vector market, 2021 - 2033 (USD Million)
  • Fig. 36 Germany viral vector market, 2021 - 2033 (USD Million)
  • Fig. 37 UK viral vector market, 2021 - 2033 (USD Million)
  • Fig. 38 France viral vector market, 2021 - 2033 (USD Million)
  • Fig. 39 Italy viral vector market, 2021 - 2033 (USD Million)
  • Fig. 40 Spain viral vector market, 2021 - 2033 (USD Million)
  • Fig. 41 Denmark viral vector market, 2021 - 2033 (USD Million)
  • Fig. 42 Sweden viral vector market, 2021 - 2033 (USD Million)
  • Fig. 43 Norway viral vector market, 2021 - 2033 (USD Million)
  • Fig. 44 Asia pacific viral vector market, 2021 - 2033 (USD Million)
  • Fig. 45 Japan viral vector market, 2021 - 2033 (USD Million)
  • Fig. 46 China viral vector market, 2021 - 2033 (USD Million)
  • Fig. 47 India viral vector market, 2021 - 2033 (USD Million)
  • Fig. 48 Australia viral vector market, 2021 - 2033 (USD Million)
  • Fig. 49 South Korea viral vector market, 2021 - 2033 (USD Million)
  • Fig. 50 Thailand viral vector market, 2021 - 2033 (USD Million)
  • Fig. 51 Latin America viral vector market, 2021 - 2033 (USD Million)
  • Fig. 52 Brazil viral vector market, 2021 - 2033 (USD Million)
  • Fig. 53 Argentina viral vector market, 2021 - 2033 (USD Million)
  • Fig. 54 Middle East and Africa viral vector market, 2021 - 2033 (USD Million)
  • Fig. 55 South Africa viral vector market, 2021 - 2033 (USD Million)
  • Fig. 56 Saudi Arabia viral vector market, 2021 - 2033 (USD Million)
  • Fig. 57 UAE viral vector market, 2021 - 2033 (USD million
  • Fig. 58 Kuwait viral vector market, 2021 - 2033 (USD Million)